Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

BIND Therapeutics Company Profile (NASDAQ:BIND)

Consensus Ratings for BIND Therapeutics (NASDAQ:BIND) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.00 (162.81% upside)

Analysts' Ratings History for BIND Therapeutics (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetDetailsShare
8/19/2014Stifel NicolausInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
7/3/2014Credit SuisseReiterated RatingOutperform$21.00 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2013Cowen and CompanyInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
10/15/2013JMP SecuritiesInitiated CoverageOutperform$30.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2013Stifel NicolausInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2013Credit SuisseInitiated CoverageOutperform$21.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 11/21/2012 forward)